Innovative Nanosuspension Formulation for Prochlorperazine and In-vitro Evaluation
Abstract
Prochlorperazine is a dopamine antagonist and is used to control nausea and vomiting. It is a BCS class II drug which has low aqueous solubility and high permeability. The present study is aimed to formulate and evaluate prochlorperazine nanosuspension to improve solubility and enhance dissolution of Prochlorperazine with varying concentrations of stabilizers such as Tween 80, PVP K30, Poloxamer 188 by using nanoprecipitation method. The developed formulations were characterized for particle size and polydispersity index, total drug content, SEM, Zeta Potential and FTIR. The invitro drug release studies and invitro drug release kinetics were performed for all formulations. FTIR studies revealed that drug is compatible with the excipients. The particle size and poly dispersity index of optimized formulation was found to be 162nm and the zeta potential was found to be -30.2 mV and concluded that the system had sufficient stability. The invitro drug release was found within their acceptable ranges. The rate of dissolution of best batch was enhanced to 93.24 in 120min. Stability studies proved that nanosuspensions were more stable with no significant changes in particle size distribution. Thus the formulated nanosuspension of prochlorperazine offers a superior conventional dosage forms for drug release
Keywords: Prochlorperazine, Nanosuspension, Solubility, Dissolution
Keywords:
Prochlorperazine, Nanosuspension, Solubility, DissolutionDOI
https://doi.org/10.22270/jddt.v13i12.6135References
Fasinu P, Pillay V, Ndesendo VM, du Toit LC, Choonara YE, Diverse approaches for the enhancement of oral drug bioavailability, Biopharm Drug Dispos, 2011; 32(4):185-209 https://doi.org/10.1002/bdd.750 PMid:21480294
Merisko-Liversidge E, Liversidge GG, Cooper ER, Nanosizing: a formulation approach for poorly-water-soluble compounds, Eur J Pharm Sci, 2003; 18(2):113-20. https://doi.org/10.1016/S0928-0987(02)00251-8 PMid:12594003
Rajalakshmi R, Venkataramudu T, Kumar AL, Sree DK, Kiranmayi D, Design & characterization of zaltoprofen nanosuspension, Inter J of Pharmacotherapy, 2012; (2)70-81.
Krishna RSM, Shivakumar HG, Gowda DV, Nanoparticles: A novel colloidal drug delivery system, Indian J Pharm Edu Res., 2006,40, 15-20.
Rawat M, Singh D, Saraf S, Saraf S, Nanocarriers promising vehicle for bioactive drugs, Biol Pharm Bull, 2006; 29(9):1790-1798. https://doi.org/10.1248/bpb.29.1790 PMid:16946487
papdiwal A, pande V, sagar K, Design & characterization of zaltoprofen nanosuspension, Der Pharma Chemica, 2014; 6(3):161-168
Wang Y, Zheng Y, Zhang L, Wang Q, Zhang D,Stability of nanosuspensions in drug delivery, J Control Release, 2013;172(3):1126-41. https://doi.org/10.1016/j.jconrel.2013.08.006 PMid:23954372
Shegokar R, Müller RH, Nanocrystals industrially feasible multifunctional formulation technology for poorly soluble actives, Int J Pharm, 2010; 399(1-2): 129-39. https://doi.org/10.1016/j.ijpharm.2010.07.044 PMid:20674732
Jane M, Agrawal S, Khan A; Formulation And Evaluation of Nanosuspension of Valsartan; Int J Curr Pharm Res,2018; 10(2): 68-74. https://doi.org/10.22159/ijcpr.2018v10i2.25874
Bhalekar R. Mangesh, Madgulkar, R. Ashwini, Shaikh G.Shagufta, Formulation and Evaluation of Chitosan- Based Mucoadhesive Buccal Patch of prochlorperazine Maleate, International Journal of Pharmacy and Pharmaceutical Research, 2018; 12 (4): 61-73
Vinod K.R, Santhosha D, Anbazhagan.S, Formulation And Evaluation of Piperine Creama New Herbal Dimensional Approach For Vitiligo Patients, International Journal of Pharmacy And Pharmaceutical Sciences, 2011; 3(2):29-33
Pandey N, Sah AN, Mahara K. Formulation and evaluation of floating microspheres of nateglinide, Int J Pharm Sci Res, 2016; 7: 453-64.
Jassem NA, Rajab NA, Formulation and in vitro evaluation of azilsartan medoxomil nanosuspension, Int J Pharm Pharm Sci, 2017; 9(6): 110-9. https://doi.org/10.22159/ijpps.2017v9i7.18917
Sumathi R, Tamizharasi S, Sivakumar T, Formulation and evaluation of polymeric nanosuspension of naringenin, Int J Appl Pharm, 2017;9(6): 60-70. https://doi.org/10.22159/ijap.2017v9i6.21674
Anjane M, Agrawal S, Khan A, Formulation and evaluation of nanosuspension of Valsartan, Int J Curr Pharm Res, 2018; 10(2): 68-74. https://doi.org/10.22159/ijcpr.2018v10i2.25874
Karakucuk A, Celebi N, Teksin ZS. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers, Design of Experiment approach, Eur J Pharm Sci, 2016; 95: 111-121. https://doi.org/10.1016/j.ejps.2016.05.010 PMid:27181836
Jawahar, N. & S.N, Meyyanathan & Senthil, Vel & Kuppusamy, Gowthamarajan & Elango, Studies on physico-chemical and pharmacokinetic properties of olanzapine through nanosuspension, Journal of Pharmaceutical Sciences and Research, 2013; 5(10): 196-202.
Patel DJ, Pandya VM, Patel JK, International Journal of Pharmaceutical Research 2009;5(2): 3318-3324
Liu D, Pan H, He F, Wang X, Li J, Yang X, et al. Effect of particle size on oral absorption of carvedilol nanosuspensions: In vitro and in vivo evaluation. Int J Nanomedicine, 2015; 10: 6425-34. https://doi.org/10.2147/IJN.S87143 PMid:26508852 PMCid:PMC4610768
Yuancai D, Wai KN, Jun H, Shoucang S, Reginald BHT (2010) A continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs. Int J Pharm 386(1-2): 256-261 https://doi.org/10.1016/j.ijpharm.2009.11.007 PMid:19922777
Patravale V.B, Date A.A, Kulkarni R.M. Nanosuspensions: A Promising Drug Delivery Strategy. Journal of Pharmacy Pharmacology. 2004:56(7): 827-840. https://doi.org/10.1211/0022357023691 PMid:15233860
Vyas Himanshu D, Parmar Ghanshyam, Shah Nirmal, Chauhan Sachin, Seth A K, Formulation and evaluation of fast dissolving film of methylcobalamin; An International Journal of Pharmaceutical Sciences; 2015; 6(4):50-68
Murthy KVR, Raju V. Development and validation of new discriminative dissolution method for carvedilol tablets, Indian J Pharm Sci, 2011;73(5):527-36. https://doi.org/10.4103/0250-474X.99000 PMid:22923865 PMCid:PMC3425064
Bajaj A, Rao MRP, Pardeshi A, Sali D. Nanocrystallization by evaporative antisolvent technique for solubility and bioavailability enhancement of telmisartan, AAPS PharmSciTech, 2012;13(4): 1331-40. https://doi.org/10.1208/s12249-012-9860-x PMid:23054986 PMCid:PMC3513472
Budama-Kilinc Y, Piperine Nanoparticles for Topical Application Preparation, Characterization, In vitro and In silico Evaluation, Chemistry Select 2019; 4(40):11693- 11700 https://doi.org/10.1002/slct.201903266
Agarwal V, Bajpai M, Preparation and Optimization of Esomeprazole Nanosuspension using Evaporative Precipitation-Ultrasonication, Tropical Journal of Pharmaceutical Research, 2014; 13 (4):497-503. https://doi.org/10.4314/tjpr.v13i4.2
Dolenc A, Govedarica B, Kocbek P, Srčič S, Kristl J, Nanosized particles of orlistat with enhanced in vitro dissolution rate and lipase inhibition, International journal of pharmaceutics, 2010;396(1-2):149-55. https://doi.org/10.1016/j.ijpharm.2010.06.003 PMid:20540997
Published
Abstract Display: 747 
PDF Downloads: 832 PDF Downloads: 192 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.